Thursday, December 10, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)



Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)


Delta, Kelowna, BC, December 10, 2020 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.


Listen to the podcast:


Read this in full at


Hear the investor ideas potcast on Spotify


Hear Investor ideas cannabis potcast on iTunes  


Today’s podcast overview/transcript:


Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.


In today’s podcast we will be looking at a few private and public company announcements.



Link Reservations Inc. (OTC: LRSV), a provider of cannabidiol (CBD) products specifically tailored for pets, announced that it is current with all of its OTC Market filings and has achieved "Current Information" status, with no risk or yields signs associated with the stock on


"I am delighted that the Company is current once again and we can focus back on the business," commented Rene Lauritsen, LinkResPet CEO. "We continue to explore the potential for growth in the CBD and wellness market and are currently assessing a number of avenues through which we can expand our presence, including further developing our product range," he added.


The Company has updated all financial reports and disclosure statements and will resume operations with its LinkResPet brand, making further announcements as new developments arise.


The Company also recently raised its Authorized Shares in order to issue shares to its CEO, Rene Lauritsen, for an acquisition that is pending which he initiated. These newly issued shares are restricted for one year per Rule 144 and if the acquisition is not completed the shares will be returned to treasury. As shareholders may note, LRSV's share structure had previously been unchanged for almost four years.


Aleafia Health Inc. (TSX: AH) (OTC: ALEAFannounced that it will commence cannabis exports to the Israeli medical cannabis market. The Company signed a binding letter of intent with Equinox International Ltd., a licensed British medical cannabis company with operations in the Israeli market.


Under the LOI, Equinox has committed to purchasing approximately 1,400 kg of dried flower in 2021. The first shipment to Equinox is expected to occur in Q1 2021 pending receipt of necessary import and export permits and completion of Aleafia’s cultivation cycle. Permit applications have already been submitted and will mark the first export of EU GACP-compliant dried flower grown at Aleafia’s Niagara Greenhouse facility.


Israel, the world’s fastest growing medical cannabis market, reached over 60,000 registered patients in 2020, from half that figure in 2018. It is also the largest net importer of cannabis globally, recently surpassing Germany.


Equinox International, in partnership with Aleafia Health, will establish an Israeli Land-to-Brand ecosystem covering supply, distribution, market leading brands and retail.


“Gaining market access to Israel, an incredibly dynamic country with a fast growing, highly innovative cannabis market, is something we’ve long aspired to,” said Aleafia Health CEO Geoffrey Benic. “Doing so with Equinox, an accomplished, internationally scaled partner, marks an exciting chapter as we commercialize Aleafia Health globally.”


“Equinox is delighted to form a Land-to-Brand strategic partnership with Aleafia Health,” said Equinox International CEO Xan Morgan. “Equinox is firmly positioned as a British champion and in partnership with Aleafia will be a leader in the Israeli cannabis market.”


The parties must now negotiate a definitive agreement concerning the supply of dried flower to Israel over a three-year term. They have agreed to negotiate the definitive agreement exclusively with one another for a period of 45 days.


Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that it has now successfully completed the import of its High THC medical cannabis product into Peru, with first prescriptions to be filled in December.


With today's announcement, Khiron becomes the first company to export High THC medical cannabis from Colombia and the only Colombian company to fill High THC prescriptions in Peru for commercial purposes. This expands the Company's product offering in Peru where sales of its High CBD product began in September 2020.

"This first shipment of Khiron's trusted High THC product into Peru represents a first in exporting High THC medical cannabis from Colombia and delivers on our strategy to increase our market impact in Peru, providing patients with reliable access to medical cannabis products. With an established pharmacy partner and data from medical cannabis prescriptions we have filled to date in Colombia, we know this will make a difference in improving the quality of life for patients in Peru," commented Alvaro Torres, Khiron CEO and Director.


As part of Khiron's Latin America expansion strategy, its High THC medical cannabis products were successfully imported into Peru as result of the Company completing all export, import and distribution requirements, including approved receipt of quotas for the Company's high THC medical cannabis by DIGEMID, Peru's drug regulatory authority. Khiron Peru is a GSP certified, registered pharmaceutical establishment, and Farmacia Universal has all required permits and licenses, including Good Manufacturing Practices (GMP) certification, to prepare magistral preparations with medical cannabis and distribute final products to patients through pharmacies under the previously announced agreement with Khiron.


The Company continues to expand medical cannabis doctor education, with almost 200 physicians from Peru having obtained their diploma accrediting completion of Khiron's medical education through the Company's program with Tecnologico de Monterrey. The Company's high THC products will focus on helping patients with serious conditions that include chronic pain, spasticity, PTSD, nausea, insomnia, anorexia and depression.


Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announced the launch of its medical cannabis program in Colombia, under compound pharmacy legislation “Formulaciones Magistrales”, in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.


Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working closely with for close to 3 years. We believe that this medical program will set the gold standard for advanced cannabinoid-based medicine in Colombia and will act as a proof of concept for planned expansions into other Latin American markets.”


The pharmaceutical cannabinoid preparations, which require physician prescription, will be commercialized through a range of business models including direct sales to patients, delivery to national pharmacies and delivery to third party medical institutions across Colombia. This comprehensive medical cannabis program is the first of its kind in Colombia to be educating and training third party health care practitioners on the efficacy of advanced cannabinoid-based medicine across various clinical indications and comorbidities and providing appropriate cannabinoid solutions. The target therapeutic areas include neurological disorders such as epilepsy, Parkinson’s disease, multiple sclerosis, psychiatric indications such as PTSD, anxiety, depression as well as chronic pain.


This first complete portfolio of advanced cannabinoid preparations comprises the same scientifically developed formulations as Avicanna’s Canadian RHO Phyto branded dosage forms including topicals, oil drops, sublingual sprays, and capsules in range of CBD only and CBD-THC ratios. The products are subjected to typical pharmaceutical drug development, including stability studies and preclinical analysis where they have demonstrated superior stability and bioavailability in comparison to basic MCT oil formulations. Avicanna continues to advance these formulations through real world evidence trials and further preclinical studies with leading Canadian institutions and clinicians. In addition to its R&D efforts, the Company continues to optimize its current formulas and expand its pipeline of products to include alternative delivery mechanisms. The active pharmaceutical ingredients for this program are sourced from Avicanna’s majority owned subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are extracted from organic and sustainably cultivated plants.


The final preparation of these products is completed through Avicanna’s own Good Production Practices (GPP) certified pharmacy lab in Bogota through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM”), which is believed to be the first of its kind to be certified for cannabinoid preparations. The education and patient support programs are also managed and operated by Avicanna’s medical team to ensure the services meet Avicanna’s quality standards and complete the full vertical integration.


“At Avicanna, our focus has always been on patients, and today, with the launch of our medical program, patients in Colombia will have access to therapeutic alternatives that may contribute to the control of their comorbidities, improving their quality of life and solving possible unmet medical needs altogether. With that, we have established ourselves as a significant contributor to the health system in Colombia, where we intend to also introduce novel pharmaceutical forms and provide optimal care,” stated Dr. Carlos Maldonado, Senior Vice President, Clinical Development at Avicanna LATAM.


Pure Extracts Technologies Corp. (CSE: PULLannounced that it has engaged a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA).

The CDSA and its Regulations provide, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial, and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

A Dealer’s Licence could allow for the following activities:

      Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction

      Research and manufacture of controlled substances such as psilocybin and psilocin

      Business to business sale of controlled substances, including by export

      Sale of controlled substance via pharmacies

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible. As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics.”

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

Submission of the Company’s Dealer’s Licence application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Learn more about our cannabis podcasts at



To hear more podcasts visit: podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.


Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708


About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:


Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at


Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download our Mobile App for iPhone and Android 

Join our Investor Club



800 665 0411




Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

No comments:

Post a Comment